ArticleCureus2026
Tocilizumab Therapy and Incident Depression in Rheumatoid Arthritis: A Retrospective Cohort Study of the All of Us Research Program.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression is a common and disabling comorbidity in rheumatoid arthritis (RA). Experimental and genetic evidence implicates interleukin-6 (IL-6) signaling in the pathogenesis of depression, but the association between pharmacologic IL-6 receptor inhibition and incident depression in patients with RA remains uncertain.
methodsWe conducted a retrospective cohort study using the National Institutes of Health's All of Us Research Program. Adults with RA and no history of depression before cohort entry were included. Tocilizumab exposure was defined by documented drug administration. The primary outcome was incident depression after the index date. Multivariable logistic regression adjusted for age, sex, race, and ethnicity, inverse probability of treatment weighting (IPTW), and Cox proportional hazards regression were used to estimate the association between tocilizumab exposure and the risk of depression.
resultsThe study included 9,826 patients with RA, including 299 treated with tocilizumab and 9,527 untreated controls. Incident depression occurred in 66 of 299 patients (22.1%) treated with tocilizumab and 3,288 of 9,527 patients (34.5%) in the untreated group. Tocilizumab was associated with a lower risk of incident depression in unadjusted analysis (odds ratio (OR), 0.54; 95% confidence interval (CI), 0.42-0.72; P<0.001). The association remained significant after multivariable adjustment (OR, 0.56; 95% CI, 0.42-0.74; P<0.001) and IPTW analysis (OR, 0.58; 95% CI, 0.54-0.61; P<0.001). Cox regression likewise demonstrated a reduced hazard of depression among tocilizumab-treated patients (adjusted hazard ratio (HR), 0.70; 95% CI, 0.55-0.90; P=0.003 by the log-rank test).
conclusionsTocilizumab therapy was associated with a significantly lower risk of incident depression among patients with RA. These findings support a potential role for IL-6 receptor blockade in modifying depression risk and warrant prospective studies to determine whether IL-6 inhibition has direct antidepressant effects independent of its effects on inflammatory disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.